140-66-9

应用筛选条件

关键词:'140-66-9'

显示 1-5 共 5 条结果关于 "140-66-9" 范围论文

Quantitation of the mRNA levels of Epo and EpoR in various tissues in the ovine fetus.

R Bruce David et al.

Molecular and cellular endocrinology, 188(1-2), 207-218 (2002-03-26)

A partial cDNA of the sheep erythropoietin receptor (EpoR) was obtained and used in real-time PCR to quantitate mRNA levels in placenta, liver and kidney throughout development (term=150 days). This was compared with Epo mRNA levels in the same tissues.

Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast.

Yurdanur Sullu et al.

Pathology, research and practice, 207(12), 747-753 (2011-10-28)

Matrix metalloproteinase-2 (MMP-2) and MMP-9 are gelatinases that play a role in the invasion and metastasis of cancer through the destruction of the basal membrane and extracellular matrix. In this study, we investigated the immunohistochemical expression of MMP-2 and MMP-9

Susceptibility to Paget's disease of bone is influenced by a common polymorphic variant of osteoprotegerin.

Anna Daroszewska et al.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 19(9), 1506-1511 (2004-08-18)

To clarify the role of the TNFRSF11B gene encoding osteoprotegerin (OPG), in Paget's disease of bone (PDB) we studied TNFRSF11B polymorphisms in an association study of 690 UK subjects and in a worldwide familial study of 66 kindreds. We found

Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice.

Timothy S Fenske et al.

Cancer research, 66(10), 5029-5038 (2006-05-19)

Secondary malignancies are a serious adverse consequence of alkylator chemotherapy. The risk of developing an alkylator-associated malignancy is influenced by genetic background, although the relevant genetic factors are poorly understood. To screen for novel susceptibility factors, we established a mouse

E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.

Taofeek K Owonikoko et al.

Cancer chemotherapy and pharmacology, 73(1), 171-180 (2013-11-30)

Sequence-dependent improved efficacy of topoisomerase I followed by topoisomerase 2 inhibitors was assessed in a randomized phase II study in extensive-stage small-cell lung cancer (SCLC). Patients with previously untreated extensive-stage SCLC with measurable disease, ECOG performance status of 0-3 and

1/1